Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE Altogether, 36 samples were classified into RAS/BRAF/NF1 mutant (n = 14, 39%) or triple wild-type (n = 22, 61%) melanoma subtypes. 31826932 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma. 31796433 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE Targeted BRAF and MEK inhibition has become an appropriate first-line treatment of BRAF-mutant advanced cutaneous melanoma. 31753111 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE Neoadjuvant BRAF-targeted therapy is associated with a high pCR rate in patients with stage III-IV melanoma, which may correlate with improved RFS and OS. 31329344 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE However, the molecular rationale for this treatment combination was based on the presence of the BRAF mutation and the efficacy observed in other cancer types such as melanoma. 31672771 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE In this review, we will focus on the current clinical development of targeted therapies beyond BRAF, in NRAS-mutated and KIT-altered melanoma. 31833955 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE We quantified cfBRAF<sup>V</sup><sup>600E</sup> by droplet digital polymerase chain reaction in plasma from 146 patients without melanoma undergoing continuous dermatological screening, from 26 stage III and seven stage IV patients with BRAF-mutant melanoma, and from 32 patients with melanoma who were free of disease for 3 or more years. 31102256 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE Mutation of the oncogene BRAF is among the most common genetic alterations in melanoma. 31744894 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE Melanoma is a deadly tumor which in recent years has been successfully treated with immune checkpoint inhibitors as PD-1/PD-L1 and CTLA-4 inhibitors and targeted therapy as BRAF and MEK inhibitors. 31785018 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE Since melanoma acquired resistance to BRAF inhibitors (BRAFi) has been associated with activation of pro-angiogenic pathways, we have investigated VEGFR-1 involvement in vemurafenib resistance. 31758648 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE Populations in Brazil, the US, Sweden, Italian, and Australia were found to be correlated to mutations of BRAF and melanoma. 31274706 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50years. 31704364 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE This study revealed an interesting finding that MMP-1 and MMP-13 protein expression in the BRAF V600 mutated melanomas were significantly lower than in the BRAF V600 wild type (P < 0.05). 31677173 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE Somatic oncogenic mutation of BRAF coupled with inactivation of PTEN constitute a frequent combination of genomic alterations driving the development of human melanoma. 31065107 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE Altogether, our data highlight heterogeneity in metabolic adaptations during acquired resistance to vemurafenib in BRAF-mutant melanoma, potentially uncovering key clinically-relevant mechanisms for combinatorial therapeutic targeting. 31819183 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE The clinical characteristics of melanoma with BRAF V600R mutation: a case series study. 31305324 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma. 31839677 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE Here we review current knowledge on how oncogenic signaling reprograms metabolism in BRAF-mutated melanoma, and discuss how NAMPT/NAD<sup>+</sup> axis contributes to these processes. 31059816 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE Small molecules tackling mutated BRAF (BRAFi) are an important mainstay of targeted therapy in a variety of cancers including melanoma. 31618797 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions. 31791701 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE The case was observed in a young patient with BRAF mutant melanoma who was started on first-line metastatic immunotherapy with pembrolisumab. 31750971 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE Confirmed partial responses were observed in patients with BRAF-mutant melanoma (n = 1) and KRAS-mutant endometrioid adenocarcinoma (n = 1). 31020608 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 GeneticVariation disease BEFREE LY3009120, a pan-RAF and dimer inhibitor, has preclinical activity in RAS- and BRAF-mutated cell lines including BRAF-mutant melanoma resistant to BRAF inhibitors. 31645440 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE Therapeutic success of targeted therapy with BRAF inhibitors (BRAFi) for melanoma is limited by resistance development. 31702822 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
1.000 Biomarker disease BEFREE We now show that the majority of BRAF/RAS WT melanoma cell lines (8/13) display some degree of sensitivity to trametinib treatment and resistance to trametinib in this melanoma subtype is associated with, but not mediated by NF1 suppression. 31518489 2020